MERCY HOSPITAL CCOP (MCCOP)

慈善医院 CCOP (MCCOP)

• 批准号: 3558674
• 负责人: WILLIAM J HEIM
• 金额: $ 6.2万
• 依托单位: MERCY HOSPITAL (SCRANTON, PA)
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-01 至 1996-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558674
• 关键词: Hodgkin's disease; acute leukemia; adenocarcinoma; androgen inhibitor; antineoplastics; behavioral medicine; biomarker; bladder neoplasm; bleomycin; breast neoplasm /cancer diagnosis; breast neoplasms; cancer information system; cancer prevention; cancer rehabilitation /care; cancer risk; carcinoma; cervix neoplasms; clinical trials; colon neoplasms; combination chemotherapy; community health services; cooperative study; cyclophosphamide; cystectomy; cytosine arabinoside; dacarbazine; doxorubicin; etoposide; flow cytometry; fluorouracil; gastrointestinal neoplasms; germ cell neoplasms; health science research analysis /evaluation; human subject; human therapy evaluation; ifosfamide; interferons; isoquinolines; kidney neoplasms; leucovorin; levamisole; lung neoplasms; lymphocytic leukemia; lymphoma; mechlorethamine; melanoma; metastasis; methotrexate; mitomycin C; mitoxantrone; multiple myeloma; myeloproliferative neoplasm; nasopharyngeal neoplasms; neoplasm /cancer chemotherapy; neoplasm /cancer education; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer radionuclide therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; oral leukoplakia; ovary neoplasms; peptide hormone analog; prednisone; procarbazine; prostate neoplasms; quality of life; radiosensitizer; rectum neoplasms; relaxation; sarcoma; smoking cessation; squamous cell carcinoma; tamoxifen; therapy compliance; tocopherols; trimetrexate; vinblastine; vincristine

Since 1986, Mercy has been a solid participant in the NCI CCOP network. Through the accomplishment of several specific aims, we intend to remain an important contributor. Our aims are: to preserve and enhance the Scranton (Mercy Hospital) CCOP base if activities, including relationships with the ECOG, RTOG, NSABP, FCCC, and MDACC: continued evaluation, implementation and monitoring of key CCOP components, such as therapeutic and cancer control protocols, IRB review, data management, and drug handling: expansion of the network to other regional hospitals; continued development of methods to involve primary care physicians and other specialists in our research component; most importantly, provide our patients with the most current Cancer Care available through NCI and our Research Bases. Several unique features of our CCOP will allow us to achieve these goals. We have access to significant population of elderly and high-risk individuals in rural and semi-rural Pennsylvania. Mercy Hospital, affiliate hospitals, and the State of PA have given CCOP a significant amount of financial and non-financial support which assures the NCI of our stability. This organization has a distinguished track record of involvement in cancer control and research activities; and has a seasoned group of investigators, who have published more than 200 articles in national medical journals. Several of our investigators are members of Research Base Protocol Committees, testifying to their commitment to the development of quality, scientifically valid, protocols. Our documented participation in cooperative group clinical research guarantees the NCI of annual accruals in excess of minimum (see graph attached). This organization possesses an excellent data management track record. Over 15 years of significant contributions to the NCI research and control, combined with our unique attributes, promise the NCI of a solid participant for the next 5 years. Researchers are participants in several Research Base Committees: We have added significantly to Cancer Control Data Management by appointing a new member to this discipline and have affiliated with MD Anderson Cancer Center and Fox Chase Cancer Center especially for their experience in cancer control protocols.

自1986年以来，Mercy一直是NCI CCOP网络的扎实参与者。 通过实现多个特定目标，我们打算保持 重要的贡献者。 我们的目标是：保存和增强斯克兰顿 （怜悯医院）CCOP基础如果活动，包括与 ECOG，RTOG，NSABP，FCCC和MDACC：继续评估，实施 并监测关键CCOP组件，例如治疗和癌症 控制方案，IRB审查，数据管理和药物处理： 将网络扩展到其他区域医院；持续发展 我们参与初级保健医生和其他专家参与的方法 研究组成部分；最重要的是，为我们的患者提供最多的 当前的癌症护理可通过NCI和我们的研究基础提供。 我们CCOP的几个独特功能将使我们能够实现这些目标。 我们可以进入大量的老年人和高风险 宾夕法尼亚州农村和半农村的个人。 慈悲医院， 会员医院和宾夕法尼亚州已向CCOP提供了重要的 确保我们的NCI的财务和非财务支持量 稳定。 该组织具有参与癌症的杰出记录 控制和研究活动；并有一个经验丰富的调查人员 他们在国家医学期刊上发表了200多篇文章。 我们的一些研究人员是研究基础协议的成员 委员会证明了他们对质量发展的承诺， 科学有效的协议。 我们记录的参与 合作小组临床研究保证了年度应计的NCI 超过最小值（请参阅图形）。 这个组织拥有一个 出色的数据管理记录。 超过15年的重要意义 对NCI研究和控制的贡献，再加上我们独特的 属性，保证未来5年的稳定参与者的NCI。 研究人员是几个研究基础委员会的参与者：我们有 通过任命新的 该学科的成员，并隶属于MD Anderson Cancer 中心和福克斯大通癌症中心，尤其是在 癌症控制方案。